About merus nv - MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
MRUS At a Glance
Merus NV
Uppsalalaan 17
Utrecht, Utrecht 3584 CM
| Phone | 31-30-253-88-00 | Revenue | 36.13M | |
| Industry | Biotechnology | Net Income | -215,326,000.00 | |
| Sector | Health Technology | Employees | 260 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MRUS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 74.737 |
| Price to Book Ratio | 4.467 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.059 |
| Enterprise Value to Sales | 60.13 |
| Total Debt to Enterprise Value | 0.005 |
MRUS Efficiency
| Revenue/Employee | 138,973.077 |
| Income Per Employee | -828,176.923 |
| Receivables Turnover | 7.672 |
| Total Asset Turnover | 0.058 |
MRUS Liquidity
| Current Ratio | 6.535 |
| Quick Ratio | 6.535 |
| Cash Ratio | 6.175 |
MRUS Profitability
| Gross Margin | N/A |
| Operating Margin | -752.96 |
| Pretax Margin | -573.368 |
| Net Margin | -595.926 |
| Return on Assets | -34.629 |
| Return on Equity | -42.882 |
| Return on Total Capital | -32.732 |
| Return on Invested Capital | -42.098 |
MRUS Capital Structure
| Total Debt to Total Equity | 1.53 |
| Total Debt to Total Capital | 1.507 |
| Total Debt to Total Assets | 1.262 |
| Long-Term Debt to Equity | 1.267 |
| Long-Term Debt to Total Capital | 1.248 |